一分钟看懂
这是一项关于尿路上皮癌的III 期研究，登记的药物或干预包括Atezolizumab；Placebo；Signatera，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、长沙、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Atezolizumab；Placebo；Signatera · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Friendship Hospital, Capital Medical University · 北京
- the First Hospital of Jilin University · 长春
- Hu Nan Provincial Cancer Hospital · 长沙
- The First Affiliated Hospital of Fujian Medical University · 福州
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Jiangsu Cancer Hospital · 南京
- Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) · 南京
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School · 南京
- Zhongshan Hospital Fudan University · 上海
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Cancer Hospital · 天津
- Yantai Yu Huangding Hospital · 烟台
公开的入选条件
- Inclusion Criteria for the Surveillance Phase:
- * Histologically confirmed MIUC (also termed transitional cell carcinoma \[TCC\]) of the bladder
- * Tumor, nodes, and metastases (TNM) classification (based on American Joint Committee on Cancer \[AJCC\] Cancer Staging Manual, 8th Edition; Amin et al. 2016) at pathological examination of surgical resection specimen as follows: For participants treated with
- * Surgical resection of MIUC of the bladder
- * Participants who have not received prior platinum-based NAC must be ineligible for cisplatin-based adjuvant chemotherapy, have refused it, or will not receive it based on physician's decision
- * ctDNA assay developed based on tumor tissue specimen and matched normal DNA from blood
- * Tumor programmed death ligand (PD-L1) expression per immunohistochemistry (IHC) that is evaluable by central testing of a representative tumor tissue specimen
- * Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan of the pelvis, abdomen, and chest no more than 4 weeks prior to enrollment
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04660344；登记信息更新于 2026-09-28。